Further Benefits With Vutrisiran Seen in FAP Patients in Phase 3 Trial

Further Benefits With Vutrisiran Seen in FAP Patients in Phase 3 Trial

305798

Further Benefits With Vutrisiran Seen in FAP Patients in Phase 3 Trial

Vutrisiran, an investigational therapy for familial amyloid polyneuropathy (FAP), eased neurological impairments, lessened heart stress, and ameliorated quality of life, nutritional status, and social engagement in adult patients, according to new nine-month data from HELIOS-A trial. “These additional data from the HELIOS-A study show the potential of vutrisiran in treating a broad group of patients with hATTR amyloidosis with polyneuropathy, with encouraging improvements seen across a range of important health and functional measures,” Pushkal Garg,…

You must be logged in to read/download the full post.